The PI3K, metabolic, and autophagy networks: Interactive partners in cellular health and disease

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 89-106

  Shanware, Naval P ^a   Bray, Kevin ^a   Abraham, Robert T ^a  

^a PFIZER INC   (United States)

Author keywords

autophagy; cancer; lysosomes; metabolism; mTOR

Indexed keywords

HYDROXYCHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TEMSIROLIMUS;

AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL CYCLE PROGRESSION; CELL METABOLISM; CELL MIGRATION; ENDOMETRIUM CANCER; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; KIDNEY CANCER; MITOGENESIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; HOMEOSTASIS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 84872231223     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010611-134717     Document Type: Review

References (100)

1. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655-57
2. Fan QW, Weiss WA. 2010. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr. Top. Microbiol. Immunol. 347:279-96
3. Hawkins PT, Anderson KE, Davidson K, Stephens LR. 2006. Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34:647-62
4. Fruman DA, Cantley LC. 2002. Phosphoinositide 3-kinase in immunological systems. Semin. Immunol. 14:7-18
5. Toker A. 2002. Phosphoinositides and signal transduction. Cell. Mol. Life Sci. 59:761-79
6. Vanhaesebroeck B, Stephens L, Hawkins P. 2012. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13:195-203
7. Gewinner C,Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, et al. 2009. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16:115-25
8. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. 2001. Cellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17:615-75
9. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-101
10. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-74
11. Carracedo A, Pandolfi PP. 2008. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27:5527-41
12. Yuan TL, Cantley LC. 2008. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497-510
13. Lunt SY, Vander Heiden MG. 2011. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27:441-64
14. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:85-95
15. Vander Heiden MG. 2011. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10:671-84
16. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. 2008. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18:54-61
17. WarburgO,Wind F,Negelein E. 1927. Themetabolism of tumors in the body. J. Gen. Physiol. 8:519-30
18. Gatenby RA, Gillies RJ. 2004. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4:891-99
19. Gillies RJ, Robey I, Gatenby RA. 2008. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49(Suppl. 2):24-42S
20. Hanahan D,Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
21. Semenza GL. 2010. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20:51-56
22. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-33
23. Locasale JW, Grassian AR,Melman T, Lyssiotis CA,Mattaini KR, et al. 2011. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43:869-74
24. Almuhaideb A, Papathanasiou N, Bomanji J. 2011. 18F-FDG PET/CT imaging in oncology. Ann. Saudi Med. 31:3-13
25. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. 2008. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14:1351-56
26. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, et al. 2007. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am. J. Roentgenol. 189:W324-30
27. Eagle H. 1955. The specific amino acid requirements of a human carcinoma cell (strain HeLa) in tissue culture. J. Exp. Med. 102:37-48
28. Daye D, Wellen KE. 2012. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 23:362-69
29. Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT. 2011. Glutamine: pleiotropic roles in tumor growth and stress resistance. J. Mol. Med. 89:229-36
30. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, et al. 2009. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458:762-65
31. Wise DR,DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, et al. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 105:18782-87
32. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. 2007. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178:93-105
33. Weinberg F, Hamanaka R, WheatonWW,Weinberg S, Joseph J, et al. 2010. Mitochondrial metabolism and ROS generation are essential forKras-mediated tumorigenicity. Proc.Natl. Acad. Sci. USA 107:8788-93
34. He C, Klionsky DJ. 2009. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 43:67-93
35. Behrends C, Sowa ME, Gygi SP, Harper JW. 2010. Network organization of the human autophagy system. Nature 466:68-76
36. Kuma A, Mizushima N. 2010. Physiological role of autophagy as an intracellular recycling system: with an emphasis on nutrient metabolism. Semin. Cell Dev. Biol. 21:683-90
37. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, et al. 2005. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171:603-14
38. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, et al. 2007. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131:1149-63
39. Kirkin V, Lamark T, Johansen T, Dikic I. 2009. NBR1 cooperates with p62 in selective autophagy of ubiquitinated targets. Autophagy 5:732-33
40. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, et al. 2007. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282:24131-45
41. Moscat J, Diaz-Meco MT. 2012. p62: a versatile multitasker takes on cancer. Trends Biochem. Sci. 37:230-36
42. Mathew R, White E. 2011. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr. Opin. Genet. Dev. 21:113-19
43. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, et al. 2004. The role of autophagy during the early neonatal starvation period. Nature 432:1032-36
44. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, et al. 2005. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J. Cell Biol. 169:425-34
45. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, et al. 2006. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10:51-64
46. Kang C, You YJ, Avery L. 2007. Dual roles of autophagy in the survival of Caenorhabditis elegans during starvation. Genes Dev. 21:2161-71
47. Christofferson DE, Yuan J. 2010. Necroptosis as an alternative form of programmed cell death. Curr. Opin. Cell Biol. 22:263-68
48. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, et al. 2011. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 25:795-800
49. Folkman J. 2006. Angiogenesis. Annu. Rev. Med. 57:1-18
50. Jain RK. 2003. Molecular regulation of vessel maturation. Nat. Med. 9:685-93
51. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. 2009. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 69:7986-93
52. Rabinowitz JD, White E. 2010. Autophagy and metabolism. Science 330:1344-48
53. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, et al. 2009. Autophagy regulates lipid metabolism. Nature 458:1131-35
54. Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7:606-19
55. Potter CJ, Pedraza LG, Xu T. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4:658-65
56. Junger MA, Rintelen F, Stocker H, Wasserman JD, Vegh M, et al. 2003. The Drosophila forkhead transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling. J. Biol. 2:20
57. Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, et al. 2006. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell. Metab. 3:35-343
58. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, et al. 2004. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-5
59. Sano H, Kane S, Sano E, Miinea CP, Asara JM, et al. 2003. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J. Biol. Chem. 278:14599-602
60. Chen S, Wasserman DH, MacKintosh C, Sakamoto K. 2011. Mice with AS160/TBC1D4-Thr649Ala knockin mutation are glucose intolerant with reduced insulin sensitivity and altered GLUT4 trafficking. Cell Metab. 13:68-79
61. Robey RB, Hay N. 2009. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19:25-31
62. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-89
63. Gross DN, van den Heuvel APJ, Birnbaum MJ. 2008. The role of FoxO in the regulation ofmetabolism. Oncogene 27:2320-36
64. Bauer DE, HatzivassiliouG,ZhaoF,Andreadis C, Thompson CB. 2005.ATPcitrate lyase is an important component of cell growth and transformation. Oncogene 24:6314-22
65. Deberardinis RJ, Lum JJ, Thompson CB. 2006. Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. J. Biol. Chem. 281:37372-80
66. Laplante M, Sabatini DM. 2009. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 19:R1046-52
67. Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21-35
68. Pe ̃ na-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, Wolff NC, Tran TA, et al. 2011. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 30:3242-58
69. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, et al. 2012. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31:1095-108
70. Inoki K, Kim J, Guan KL. 2012. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 52:381-400
71. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, et al. 2011. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 25:460-70
72. Lock R, Roy S, Kenific CM, Su JS, Salas E, et al. 2011. Autophagy facilitates glycolysis during Rasmediated oncogenic transformation. Mol. Biol. Cell 22:165-78
73. Yang S, Wang X, Contino G, Liesa M, Sahin E, et al. 2011. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25:717-29
74. Castellano E, Downward J. 2011. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2:261-74
75. Cheong H, Lindsten T,Wu J, Lu C, Thompson CB. 2011. Ammonia-induced autophagy is independent of ULK1/ULK2 kinases. Proc. Natl. Acad. Sci. USA 108:11121-26
76. Eng CH, Yu K, Lucas J, White E, Abraham RT. 2010. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci. Signal. 3:ra31
77. Sancak Y, Sabatini DM. 2009. Rag proteins regulate amino-acid-induced mTORC1 signalling. Biochem. Soc. Trans. 37:289-90
78. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. 2011. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolarH+-ATPase. Science 334:678-83
79. Heublein S, Kazi S, Ogmundsdottir MH, Attwood EV, Kala S, et al. 2010. Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation. Oncogene 29:4068-79
80. Rong Y, McPhee CK, Deng S, HuangL,Chen L, et al. 2011. Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation. Proc. Natl. Acad. Sci. USA 108:7826-31
81. Narita M, Young AR, Arakawa S, Samarajiwa SA, Nakashima T, et al. 2011. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science 332:966-70
82. Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, et al. 2010. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 465:942-46
83. Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, et al. 2011. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol. Cell 44:134-46
84. ZhengM,Wang YH,WuXN,Wu SQ, Lu BJ, et al. 2011. Inactivation ofRheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. Nat. Cell Biol. 13:263-72
85. CombWC,Hutti JE,Cogswell P, Cantley LC, Baldwin AS. 2012. p85αSH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol. Cell 45:719-30
86. Chalkiadaki A, Guarente L. 2012. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat. Rev. Endocrinol. 8:287-96
87. Frescas D, Valenti L, Accili D. 2005. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J. Biol. Chem. 280:20589-95
88. Azad MB, Chen Y, Gibson SB. 2009. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox Signal. 11:777-90
89. Scherz-Shouval R, Elazar Z. 2011. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem. Sci. 36:30-38
90. Goldstein BJ. 2002. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J. Clin. Endocrinol. Metab. 87:2474-80
91. Meng TC, Fukada T, Tonks NK. 2002. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell 9:387-99
92. Garcia JA, Danielpour D. 2008. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol. Cancer Ther. 7:1347-54
93. Khokhar NZ, Altman JK, Platanias LC. 2011. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr. Opin. Oncol. 23:578-86
94. Schenone S, Brullo C, Musumeci F, Radi M, Botta M. 2011. ATP-competitive inhibitors of mTOR: an update. Curr. Med. Chem. 18:2995-3014
95. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, et al. 2011. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71
96. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, et al. 2011. PI3K inhibition results in enhanced HERsignaling and acquiredERKdependency in HER2-overexpressing breast cancer. Oncogene 30:2547-57
97. Amaravadi RK,Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, et al. 2011. Principles and current strategies for targeting autophagy for cancer treatment. Clin. Cancer Res. 17:654-66
98. Vezmar M, Georges E. 1998. Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem. Pharmacol. 56:733-42
99. Mizushima N, Levine B. 2010. Autophagy inmammalian development and differentiation. Nat. Cell Biol. 12:823-30
100. Sheen JH, Zoncu R, Kim D, Sabatini DM. 2011. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 19:613-28